{ "FullStudy":{ "Rank":217806, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01516593", "OrgStudyIdInfo":{ "OrgStudyId":"CARMEN" }, "Organization":{ "OrgFullName":"IRCCS San Raffaele", "OrgClass":"OTHER" }, "BriefTitle":"Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma", "OfficialTitle":"Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma", "Acronym":"CARMEN" }, "StatusModule":{ "StatusVerifiedDate":"January 2012", "OverallStatus":"Unknown status", "LastKnownStatus":"Recruiting", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"November 2011" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"April 2013", "PrimaryCompletionDateType":"Anticipated" }, "CompletionDateStruct":{ "CompletionDate":"August 2015", "CompletionDateType":"Anticipated" }, "StudyFirstSubmitDate":"January 6, 2012", "StudyFirstSubmitQCDate":"January 24, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 25, 2012", "StudyFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"January 24, 2012", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"January 25, 2012", "LastUpdatePostDateType":"Estimate" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor-Investigator", "ResponsiblePartyInvestigatorFullName":"Andres J. M. Ferreri", "ResponsiblePartyInvestigatorTitle":"MD", "ResponsiblePartyInvestigatorAffiliation":"IRCCS San Raffaele" }, "LeadSponsor":{ "LeadSponsorName":"Andres J. M. Ferreri", "LeadSponsorClass":"OTHER" } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"This is a multicenter,open-label trial to evaluate activity and safety of the investigational intensive in HIV+ patients with Burkitt's lymphoma.\n\nExperimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.\n\nUntil recently, the immuno-compromised state of patients with concomitant HIV/AIDS and BL was thought to limit the ability to administer intensive chemotherapeutic regimens due to infection rate. However, the advent of highly active antiretroviral therapy (HAART) and evidence in diffuse large B-cell lymphomas that HIV-positive patients can tolerate standard chemotherapeutic regimens with improved outcomes have led investigators to treat HIV-positive patients with the same intensive chemotherapy regimens used to treat immuno-competent patients. Data suggest that these current approaches, along with supportive care, may result in improved patient outcomes, similar to those in the immuno-competent patient population.", "DetailedDescription":"The activity of feasibility of the proposed program will be assessed in HIV+ patients with Burkitt lymphoma with the aim to improve tolerability, minimize source consuming and supporting treatment and redu ce late sequels. Available combinations in this setting are really source demanding and toxic combinations showing high rates of septic complication and a treatment-related mortality of near 20%." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "HIV", "Burkitt's Lymphoma" ] }, "KeywordList":{ "Keyword":[ "HIV", "Burkitt's lymphoma", "intensive", "short term", "immuno-chemotherapy", "HIV-positive patients with Burkitt's lymphoma" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 2" ] }, "DesignInfo":{ "DesignInterventionModel":"Single Group Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"None (Open Label)" } }, "EnrollmentInfo":{ "EnrollmentCount":"19", "EnrollmentType":"Anticipated" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"intensive short term immuno-chemotherapy", "ArmGroupType":"Experimental", "ArmGroupDescription":"Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: Induction Phase", "Drug: Consolidation Phase (on day +50)", "Drug: Intensification phase", "Drug: BEAM conditioning", "Radiation: Consolidation radiotherapy" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"Induction Phase", "InterventionDescription":"dd -2 to 1: Methylprednisolone\ndd 0-1, Cyclophosphamide, associated on day 0 with Vincristine\ndd 2, Rituximab\ndd 7, Methotrexate\ndd 14, Rituximab\ndd 15, Etoposide\ndd 21, Methotrexate\ndd 29, Rituximab and Doxorubicin\ndd 36, Rituximab and VCR\n\nAt the end of this induction phase, subsequent treatment will be performed according to the objective response:\n\npts in CR: consolidation phase followed by bulky site irradiation\npts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation\npts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "intensive short term immuno-chemotherapy" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "Short-term intensive sequential chemoimmunotherapy" ] } },{ "InterventionType":"Drug", "InterventionName":"Consolidation Phase (on day +50)", "InterventionDescription":"dd 1-2: cytarabine twice a day\ndd 3 and 11: rituximab\ndd 11-13: leukapheresis for PBPC collection.", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "intensive short term immuno-chemotherapy" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "high-dose cytarabine; consolidation phase" ] } },{ "InterventionType":"Drug", "InterventionName":"Intensification phase", "InterventionDescription":"One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.\nCTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);\nAraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed).", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "intensive short term immuno-chemotherapy" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "unresponsive patients, refractory disease" ] } },{ "InterventionType":"Drug", "InterventionName":"BEAM conditioning", "InterventionDescription":"BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "intensive short term immuno-chemotherapy" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "Conditioning regimen, autologous transplantation" ] } },{ "InterventionType":"Radiation", "InterventionName":"Consolidation radiotherapy", "InterventionDescription":"At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "intensive short term immuno-chemotherapy" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "bulky irradiation; residual lesion" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"evaluation of activity of the induction phase in terms of complete remission rate", "PrimaryOutcomeDescription":"Objective lymphoma response achieved after the induction phase of the experimental treatment.", "PrimaryOutcomeTimeFrame":"at the end of the induction phase of the investigational intensive chemotherapy, an expected average of 45 days" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"Feasibility and tolerability of the investigational intensive chemotherapy in terms of grade ≥4 adverse events", "SecondaryOutcomeDescription":"Assessment of incidence of grade 4 AE during experimental treatment (induction, consolidation and intensification phases as well as conditioning and autologous stem cell transplantation (if indicated)", "SecondaryOutcomeTimeFrame":"participants will be followed for the duration of the whole experimental program, an expected average of 100 days" },{ "SecondaryOutcomeMeasure":"Feasibility and tolerability of the consolidation phase followed by BEAM conditioning and autologous stem cell transplantation in terms of prevalence of grade ≥4 adverse events", "SecondaryOutcomeTimeFrame":"participants will be followed for the duration of the whole experimental program, an expected average of 100 days" },{ "SecondaryOutcomeMeasure":"Feasibility and tolerability of intensification phase in terms of prevalence of grade ≥4 adverse events", "SecondaryOutcomeDescription":"Participants who will not achieve a complete or partial response after induction and consolidation phases will be referred to intensification phase, which will be followed by BEAM + ASCT. These patients will be assess for tolerabbility and AE during these therapeutic phases.", "SecondaryOutcomeTimeFrame":"participants will be followed for the duration of the whole experimental program, an expected average of 100 days" },{ "SecondaryOutcomeMeasure":"Activity of the whole investigational program in terms of complete remission rate", "SecondaryOutcomeDescription":"Participants will be assessed by conventional exams to define complete remission rate after the whole experiemntal program; that is after consolidation phase for patients who achieved complete remission after induction phase, after BEAM + ASCt for patients who achieved partial response after induction phase, and after intensification phase for patients who did not achieve an objective response after induction phase.", "SecondaryOutcomeTimeFrame":"at the end of the whole program, an expected average of 100 days" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nHistologic diagnosis of Burkitt's lymphoma (WHO 2008)\nHIV sero-positivity\nAge ≥18 and ≤60 years\nECOG-PS ≤3\n\nExclusion Criteria:\n\nCNS parenchymal involvement\nAbsolute neutrophil count <1.000 cells/μL and platelets count <75 × 109/L (Burkitt unrelated)\nCreatinine >1,5N (Burkitt unrelated)\nSGOT and/or SGTP >2,5N (Burkitt unrelated)\nBilirubin >2N (Burkitt unrelated)\nSevere psychiatric illness or any other clinical, social or psychological condition that could interfere with patient's adherence and compliance\nSignificant cardiac disease or acute myocardial infarction in the last 12 months\nSevere active infection (except for HBV and/or HCV co-infection)", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"18 Years", "MaximumAge":"60 Years", "StdAgeList":{ "StdAge":[ "Adult" ] } }, "ContactsLocationsModule":{ "CentralContactList":{ "CentralContact":[ { "CentralContactName":"Andrés JM Ferreri, MD", "CentralContactRole":"Contact", "CentralContactPhone":"+39022643", "CentralContactPhoneExt":"7649", "CentralContactEMail":"ferreri.andres@hsr.it" },{ "CentralContactName":"Marta Bruno Ventre, MD", "CentralContactRole":"Contact", "CentralContactPhone":"+39022643", "CentralContactPhoneExt":"7612", "CentralContactEMail":"brunoventre.marta@hsr.it" } ] }, "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Andrés JM Ferreri, MD", "OverallOfficialAffiliation":"San Raffaele Scientific Institute, Milano, Italy", "OverallOfficialRole":"Study Chair" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Oncologia Medica A - Centro di Riferimento Oncologico", "LocationStatus":"Not yet recruiting", "LocationCity":"Aviano (PN)", "LocationCountry":"Italy", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"Michele Spina, MD", "LocationContactRole":"Contact", "LocationContactPhone":"+300434659", "LocationContactPhoneExt":"284", "LocationContactEMail":"mspina@cro.it" },{ "LocationContactName":"Michele Spina, MD", "LocationContactRole":"Principal Investigator" } ] } },{ "LocationFacility":"Ematologia - A.O. Spedali Civili", "LocationStatus":"Not yet recruiting", "LocationCity":"Brescia", "LocationCountry":"Italy", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"Alessandro Re, MD", "LocationContactRole":"Contact", "LocationContactPhone":"+39030399", "LocationContactPhoneExt":"5438", "LocationContactEMail":"sandrore@aruba.it" },{ "LocationContactName":"Alessandro Re, MD", "LocationContactRole":"Principal Investigator" } ] } },{ "LocationFacility":"Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte Tabor", "LocationStatus":"Recruiting", "LocationCity":"Milano", "LocationCountry":"Italy", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"Andrés JM Ferreri, MD", "LocationContactRole":"Contact", "LocationContactPhone":"+39022643", "LocationContactPhoneExt":"7649", "LocationContactEMail":"ferreri.andres@hsr.it" },{ "LocationContactName":"Marta Bruno Ventre, MD", "LocationContactRole":"Contact", "LocationContactEMail":"brunoventre.marta@hsr.it" },{ "LocationContactName":"Andrés JM Ferreri, MD", "LocationContactRole":"Principal Investigator" } ] } },{ "LocationFacility":"S.C. Oncologia Medica - Ospedale San Paolo", "LocationStatus":"Not yet recruiting", "LocationCity":"Milano", "LocationCountry":"Italy", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"Niccolò Frungillo, MD", "LocationContactRole":"Contact", "LocationContactEMail":"niccolo.frungillo@ao.sanpaolo.it" },{ "LocationContactName":"Niccolò Frungillo, MD", "LocationContactRole":"Principal Investigator" } ] } },{ "LocationFacility":"S.C. Oncologia Medica 3 - IRCCS Istituto Nazionale Tumori (INT)", "LocationStatus":"Not yet recruiting", "LocationCity":"Milano", "LocationCountry":"Italy", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"Massimo Di Nicola, MD", "LocationContactRole":"Contact", "LocationContactPhone":"+39022390", "LocationContactPhoneExt":"2360", "LocationContactEMail":"massimo.dinicola@istitutotumori.mi.it" },{ "LocationContactName":"Massimo Di Nicola, MD", "LocationContactRole":"Principal Investigator" } ] } },{ "LocationFacility":"U.O.C. Immunodeficienze virali - I.N.M.I. L. Spallanzani", "LocationStatus":"Not yet recruiting", "LocationCity":"Roma", "LocationCountry":"Italy", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"Andrea Antinori, MD", "LocationContactRole":"Contact", "LocationContactPhone":"+390655170", "LocationContactPhoneExt":"348", "LocationContactEMail":"andrea.antinori@inmi.it" },{ "LocationContactName":"Andrea Antinori, MD", "LocationContactRole":"Principal Investigator" } ] } },{ "LocationFacility":"S.C. Oncoematologia - A.O. Santa Maria", "LocationStatus":"Not yet recruiting", "LocationCity":"Terni", "LocationCountry":"Italy", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"Anna Marina Liberati, MD", "LocationContactRole":"Contact", "LocationContactPhone":"+390744205", "LocationContactPhoneExt":"971", "LocationContactEMail":"marinal@unipg.it" },{ "LocationContactName":"Anna Marina Liberati, MD", "LocationContactRole":"Principal Investigator" } ] } },{ "LocationFacility":"U.O. Ematologia 2 - Ospedale San Giovanni Battista", "LocationStatus":"Not yet recruiting", "LocationCity":"Torino", "LocationCountry":"Italy", "LocationContactList":{ "LocationContact":[ { "LocationContactName":"Dino Allione, MD", "LocationContactRole":"Contact", "LocationContactPhone":"+39011633", "LocationContactPhoneExt":"6685", "LocationContactEMail":"ballione@molinette.piemonte.it" },{ "LocationContactName":"Dino Allione, MD", "LocationContactRole":"Principal Investigator" } ] } } ] } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"D000003561", "InterventionMeshTerm":"Cytarabine" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000000964", "InterventionAncestorTerm":"Antimetabolites, Antineoplastic" },{ "InterventionAncestorId":"D000000963", "InterventionAncestorTerm":"Antimetabolites" },{ "InterventionAncestorId":"D000045504", "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action" },{ "InterventionAncestorId":"D000000970", "InterventionAncestorTerm":"Antineoplastic Agents" },{ "InterventionAncestorId":"D000000998", "InterventionAncestorTerm":"Antiviral Agents" },{ "InterventionAncestorId":"D000000890", "InterventionAncestorTerm":"Anti-Infective Agents" },{ "InterventionAncestorId":"D000007166", "InterventionAncestorTerm":"Immunosuppressive Agents" },{ "InterventionAncestorId":"D000007155", "InterventionAncestorTerm":"Immunologic Factors" },{ "InterventionAncestorId":"D000045505", "InterventionAncestorTerm":"Physiological Effects of Drugs" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M5349", "InterventionBrowseLeafName":"Cytarabine", "InterventionBrowseLeafAsFound":"Cytarabine", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M2862", "InterventionBrowseLeafName":"Antimetabolites", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2895", "InterventionBrowseLeafName":"Antiviral Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2795", "InterventionBrowseLeafName":"Anti-Infective Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M8795", "InterventionBrowseLeafName":"Immunosuppressive Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M8784", "InterventionBrowseLeafName":"Immunologic Factors", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"Infe", "InterventionBrowseBranchName":"Anti-Infective Agents" },{ "InterventionBrowseBranchAbbrev":"ANeo", "InterventionBrowseBranchName":"Antineoplastic Agents" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000002051", "ConditionMeshTerm":"Burkitt Lymphoma" },{ "ConditionMeshId":"D000006679", "ConditionMeshTerm":"HIV Seropositivity" },{ "ConditionMeshId":"D000008223", "ConditionMeshTerm":"Lymphoma" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000009370", "ConditionAncestorTerm":"Neoplasms by Histologic Type" },{ "ConditionAncestorId":"D000009369", "ConditionAncestorTerm":"Neoplasms" },{ "ConditionAncestorId":"D000008232", "ConditionAncestorTerm":"Lymphoproliferative Disorders" },{ "ConditionAncestorId":"D000008206", "ConditionAncestorTerm":"Lymphatic Diseases" },{ "ConditionAncestorId":"D000007160", "ConditionAncestorTerm":"Immunoproliferative Disorders" },{ "ConditionAncestorId":"D000007154", "ConditionAncestorTerm":"Immune System Diseases" },{ "ConditionAncestorId":"D000020031", "ConditionAncestorTerm":"Epstein-Barr Virus Infections" },{ "ConditionAncestorId":"D000006566", "ConditionAncestorTerm":"Herpesviridae Infections" },{ "ConditionAncestorId":"D000004266", "ConditionAncestorTerm":"DNA Virus Infections" },{ "ConditionAncestorId":"D000014777", "ConditionAncestorTerm":"Virus Diseases" },{ "ConditionAncestorId":"D000014412", "ConditionAncestorTerm":"Tumor Virus Infections" },{ "ConditionAncestorId":"D000016393", "ConditionAncestorTerm":"Lymphoma, B-Cell" },{ "ConditionAncestorId":"D000008228", "ConditionAncestorTerm":"Lymphoma, Non-Hodgkin" },{ "ConditionAncestorId":"D000015658", "ConditionAncestorTerm":"HIV Infections" },{ "ConditionAncestorId":"D000016180", "ConditionAncestorTerm":"Lentivirus Infections" },{ "ConditionAncestorId":"D000012192", "ConditionAncestorTerm":"Retroviridae Infections" },{ "ConditionAncestorId":"D000012327", "ConditionAncestorTerm":"RNA Virus Infections" },{ "ConditionAncestorId":"D000015229", "ConditionAncestorTerm":"Sexually Transmitted Diseases, Viral" },{ "ConditionAncestorId":"D000012749", "ConditionAncestorTerm":"Sexually Transmitted Diseases" },{ "ConditionAncestorId":"D000007153", "ConditionAncestorTerm":"Immunologic Deficiency Syndromes" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M9803", "ConditionBrowseLeafName":"Lymphoma", "ConditionBrowseLeafAsFound":"Lymphoma", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M16833", "ConditionBrowseLeafName":"HIV Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M2103", "ConditionBrowseLeafName":"Acquired Immunodeficiency Syndrome", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8325", "ConditionBrowseLeafName":"HIV Seropositivity", "ConditionBrowseLeafAsFound":"HIV-Positive", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M3903", "ConditionBrowseLeafName":"Burkitt Lymphoma", "ConditionBrowseLeafAsFound":"Burkitt lymphoma", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M10898", "ConditionBrowseLeafName":"Neoplasms by Histologic Type", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M9808", "ConditionBrowseLeafName":"Lymphoproliferative Disorders", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M9786", "ConditionBrowseLeafName":"Lymphatic Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8789", "ConditionBrowseLeafName":"Immunoproliferative Disorders", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8783", "ConditionBrowseLeafName":"Immune System Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8866", "ConditionBrowseLeafName":"Infection", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M4951", "ConditionBrowseLeafName":"Communicable Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M16105", "ConditionBrowseLeafName":"Virus Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M20465", "ConditionBrowseLeafName":"Epstein-Barr Virus Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8226", "ConditionBrowseLeafName":"Herpesviridae Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M6025", "ConditionBrowseLeafName":"DNA Virus Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M15745", "ConditionBrowseLeafName":"Tumor Virus Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M17411", "ConditionBrowseLeafName":"Lymphoma, B-Cell", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M9805", "ConditionBrowseLeafName":"Lymphoma, Non-Hodgkin", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M17223", "ConditionBrowseLeafName":"Lentivirus Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13609", "ConditionBrowseLeafName":"Retroviridae Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13732", "ConditionBrowseLeafName":"RNA Virus Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14141", "ConditionBrowseLeafName":"Sexually Transmitted Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M16516", "ConditionBrowseLeafName":"Sexually Transmitted Diseases, Viral", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14938", "ConditionBrowseLeafName":"Syndrome", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8782", "ConditionBrowseLeafName":"Immunologic Deficiency Syndromes", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"T3556", "ConditionBrowseLeafName":"Lymphosarcoma", "ConditionBrowseLeafAsFound":"Lymphoma", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"T895", "ConditionBrowseLeafName":"Burkitt Lymphoma", "ConditionBrowseLeafAsFound":"Burkitt lymphoma", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"T642", "ConditionBrowseLeafName":"B-cell Lymphoma", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC04", "ConditionBrowseBranchName":"Cancers and Other Neoplasms" },{ "ConditionBrowseBranchAbbrev":"BC15", "ConditionBrowseBranchName":"Blood and Lymph Conditions" },{ "ConditionBrowseBranchAbbrev":"BC20", "ConditionBrowseBranchName":"Immune System Diseases" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC02", "ConditionBrowseBranchName":"Viral Diseases" },{ "ConditionBrowseBranchAbbrev":"BC01", "ConditionBrowseBranchName":"Bacterial and Fungal Diseases" },{ "ConditionBrowseBranchAbbrev":"BXS", "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions" },{ "ConditionBrowseBranchAbbrev":"BC23", "ConditionBrowseBranchName":"Symptoms and General Pathology" },{ "ConditionBrowseBranchAbbrev":"Rare", "ConditionBrowseBranchName":"Rare Diseases" } ] } } } } } }